142 related articles for article (PubMed ID: 36476926)
21. Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs.
Ofori K; Bhagat G; Rai AJ
Br J Clin Pharmacol; 2021 Feb; 87(2):284-294. PubMed ID: 33080045
[TBL] [Abstract][Full Text] [Related]
22. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
[TBL] [Abstract][Full Text] [Related]
23. Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.
Melani C; Roschewski M
Oncology (Williston Park); 2016 Aug; 30(8):731-8, 744. PubMed ID: 27539624
[TBL] [Abstract][Full Text] [Related]
24. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
[TBL] [Abstract][Full Text] [Related]
25. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.
Melani C; Wilson WH; Roschewski M
Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398
[TBL] [Abstract][Full Text] [Related]
26. Liquid biopsy in hematological malignancies: current and future applications.
Talotta D; Almasri M; Cosentino C; Gaidano G; Moia R
Front Oncol; 2023; 13():1164517. PubMed ID: 37152045
[TBL] [Abstract][Full Text] [Related]
27. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma.
Hu R; Winter A; Hill BT
Curr Oncol Rep; 2019 Apr; 21(5):44. PubMed ID: 30941515
[TBL] [Abstract][Full Text] [Related]
28. ctDNA predicts outcomes in DLBCL.
Sidaway P
Nat Rev Clin Oncol; 2018 Nov; 15(11):655. PubMed ID: 30177684
[No Abstract] [Full Text] [Related]
29. Histological transformation in malignant lymphoma: a possible role of PET/CT and circulating tumor DNA as noninvasive diagnostic tools.
Ohmoto A; Fuji S
Expert Rev Hematol; 2020 Jan; 13(1):23-30. PubMed ID: 31701788
[No Abstract] [Full Text] [Related]
30. Circulating tumor DNA in Hodgkin lymphoma.
Maco M; Kupcova K; Herman V; Ondeckova I; Kozak T; Mocikova H; Havranek O;
Ann Hematol; 2022 Nov; 101(11):2393-2403. PubMed ID: 36074181
[TBL] [Abstract][Full Text] [Related]
31. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
32. [Circulating Tumor DNA Analysis in Lymphomas].
Suehara Y
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1209-1213. PubMed ID: 34657049
[TBL] [Abstract][Full Text] [Related]
33. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
35. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.
Rivas-Delgado A; Nadeu F; Enjuanes A; Casanueva-Eliceiry S; Mozas P; Magnano L; Castrejón de Anta N; Rovira J; Dlouhy I; Martín S; Osuna M; Rodríguez S; Simó M; Pinyol M; Baumann T; Beà S; Balagué O; Delgado J; Villamor N; Setoain X; Campo E; Giné E; López-Guillermo A
Clin Cancer Res; 2021 Jan; 27(2):513-521. PubMed ID: 33122345
[TBL] [Abstract][Full Text] [Related]
36. Liquid biopsy in tissue-born lymphomas.
Spina V; Rossi D
Swiss Med Wkly; 2019 Jan; 149():w14709. PubMed ID: 30673117
[TBL] [Abstract][Full Text] [Related]
37. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
[No Abstract] [Full Text] [Related]
38. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
Lauer EM; Mutter J; Scherer F
Leukemia; 2022 Sep; 36(9):2151-2164. PubMed ID: 35701522
[TBL] [Abstract][Full Text] [Related]
39. Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma.
Lv L; Liu Y
Front Oncol; 2021; 11():658234. PubMed ID: 33816315
[TBL] [Abstract][Full Text] [Related]
40. [Research progress of prognostic biomarkers in diffuse large B-cell lymphoma].
Chen HZ; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):989-995. PubMed ID: 33342153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
